On May 13, 2022, a toxicity study Published by NNB (https://journals.sagepub.com/doi/abs/10.1177%2F10915818221094487) was designed to evaluate the safety and toxic potentials of MitoBurn(L-BAIBA), where L-BAIBA was administered orally to Sprague Dawley rats at 100, 300, and 900 mg/kg/day for 90 days. The study shows that no treatment-related adverse effects were observed in any of the treatment groups. Based on the results, the No-Observed-Adverse-Effect Level (NOAEL) of L-BAIBA was 900 mg/kg/day. This study is the first study to access the safety profile of L-BAIBA in an in vivo repeated dose subchronic toxicity stud by oral (gavage) route in Sprague Dawley rats.
MitoBurn® L-BAIBA(β-aminoisobutyric acid) , is a signaling molecule secreted by exercising muscles that triggers the adaptive response mechanisms. Increasing L-BAIBA levels augments the results of exercise and provides many of the benefits of regular exercise, without exercising. Many research showed that MitoBurn can improve carb tolerance and insulin sensitivity. L-BAIBA is triggered by the PGC-1α protein from exercising muscles. It plays a powerful role behind the benefits of regular exercise, and initiates the “browning” of white adipose tissue, which increases energy expenditure and helps regulate weight management during EODF (every-other-day fasting). This novel ingredients great for athletes trying to get more out of their workout, casually active individuals looking to amplify diet and workout as well as those looking for healthy ways to get leaner and more fit.
This ingredient is currently favored by a large number of people who enjoy fitness and pay attention to weight management. It’s important to note that this toxicology report published by NNB has never been done by others before. Therefore, this study undoubtedly added great commercial value to MitoBurn®. NNB also believes this study will also allow brand owners who are still on the sidelines to use MitoBurn® with confidence.